Hydrix Limited (AU:HYD) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Hydrix Limited has announced a significant adjustment to the book value of its investment in Avertix Medical, reducing it by A$1.75 million following Avertix’s recent Series C funding terms and a 100-to-1 reverse stock split. This move brings the total value of Hydrix Ventures’ investment portfolio down to A$3.41 million. The adjustment reflects a recalibrated stock price of US$9.27 per share for Avertix, the developer of the Guardian heart attack alert device.
For further insights into AU:HYD stock, check out TipRanks’ Stock Analysis page.